Original contributionProton MR spectroscopic imaging of the striatum in Parkinson's disease
References (34)
- et al.
Spatially resolved high resolution spectroscopy by “four dimensional” NMR
J. Magn. Reson.
(1983) - et al.
The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium
Magn. Reson. Imaging
(1993) - et al.
Spectroscopic imaging display and analysis
Magn. Reson. Imaging
(1992) Striatonigral degeneration
Pathology
(1978)- et al.
Multiple system atrophy with autonomic failure: Clinical, histological and neurochemical observations on four cases
J. Neurol. Sci.
(1979) Magnetic resonance imaging in parkinsonism
Neurol. Clin.
(1992)Positron emission tomography studies in parkinsonism
Neurol. Clin.
(1992)Multiple system atrophy—the nature of the beast
J. Neurol. Neurosurg. Psychiatry special supplement
(1989)- et al.
NMR chemical shift imaging in three dimensions
- et al.
MR proton spectroscopy in multiple sclerosis
AJNR
(1992)
Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published erratum appears in Neurology 1991 Nov; 41 (11): 1828]
Neurology
Proton MR spectroscopy in multiple sclerosis: Value in establishing diagnosis, monitoring progression, and evaluating therapy
AJR
Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study
Stroke
Human brain infarction: proton MR spectroscopy
Radiology
Combined magnetic resonance imaging and proton magnetic resonance spectroscopy of patients with acute stroke
Stroke
Proton magnetic resonance spectroscopy of human brain: applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities
Magn. Reson. Med.
Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging
J. Comput. Assist. Tomogr.
Cited by (32)
The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes
2015, Parkinsonism and Related DisordersMetabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study
2015, Neuroscience LettersCitation Excerpt :Previous studies on PD found abnormal 1H-MRS spectra, by using long TE, in basal ganglia compared with control subjects [5–6,21–23,26–28]. However, no significant differences in metabolite profile between PD patients and control subjects, either in terms of metabolite ratios [29–30] or absolute concentrations [26,31], have also been reported. Many researchers showed significant changes of NAA and other metabolite levels in cortical regions involved in striatal circuit.
Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: In vivo <sup>1</sup>H-MRS study of an animal model for Parkinson's disease
2011, Magnetic Resonance ImagingCitation Excerpt :However, some conflicting results have been reported in the clinical and preclinical PD research. Two clinical studies did not show any difference in NAA/Cr and NAA/Cho ratios between patients with PD and controls [49,50], and two preclinical studies observed no significant decreases in the NAA/Cr ratio in the striatum of MPTP-treated mice [29,30]. Another 1H-MRS study detected a lactate peak as an inverted doublet pattern at 1.33 ppm in all MPTP-treated cats, but not in the control or the pargyline+MPTP cats [46].
Simultaneous determination of N-acetylaspartylglutamate and N-acetylaspartate in rat brain homogenate using high-performance liquid chromatography with pre-column fluorescence derivatization
2008, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesQuantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease
2007, Neurobiology of DiseaseCitation Excerpt :In this regard, imaging research activities for PD have focused on finding better means to assess nigrostriatal degeneration. Functional imaging including single photon emission computerized tomography (Benamer et al., 2000), positron emission tomography (Eidelberg et al., 1995; Morrish et al., 1996), proton magnetic resonance spectroscopic imaging (1H MRSI) (Cruz et al., 1997; Boska et al., 2005), and functional magnetic resonance imaging (Ceballos-Baumann, 2003) have all proved promising but not definitive. One promising and new approach that has gained attention for tracking age-related changes in human brain and for the diagnosis of neurodegenerative diseases is magnetic resonance diffusion tensor imaging (DTI) (McGraw et al., 2005).